Tatsuya Yoshida

25PUBLICATIONS
186CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Jul 11, 2025
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915.

Georgina V Long, Hao Tang, Keyur Desai

|Jun 24, 2025
Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors.

Faisal Fa'ak, Nicolas Coudray, George Jour

|Oct 08, 2024
Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.

Jeffrey S Weber, Mark R Middleton, Georgia Yates

|Aug 08, 2024
Tyrosine Protein Kinase SYK-Related Gene Signature in Baseline Immune Cells Associated with Adjuvant Immunotherapy-Induced Immune-Related Adverse Events in Melanoma.

Kelsey R Monson, Robert Ferguson, Joanna E Handzlik

|Aug 08, 2024
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.

Justin F Gainor, Manish R Patel, Jeffrey S Weber

|Aug 05, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.

Jeffrey Weber, Michele Del Vecchio, Mario Mandalá

Pageof 5

Frequent Collaborators

7 joint publications

Nikhil I Khushalani

6 joint publications

Paolo Antonio Ascierto

4 joint publications

Mario Mandala

4 joint publications

Michael B Atkins